[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352320-105":59,"doc-detail-352320-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","immune-related-adverse-events-and-neutrophil-to-lymphocyte-ratio-as-prognostic-indicators-in-gynecologic-cancer-patients-receiving-pembrolizumab-a-real-world-analysis","Immune-related adverse events and neutrophil-to-lymphocyte ratio as prognostic indicators in gynecologic cancer patients receiving pembrolizumab - a real-world analysis","","Retrospective real-world analysis evaluated whether immune-related adverse events and the pretreatment neutrophil-to-lymphocyte ratio can predict treatment response and survival in gynecologic cancer patients receiving pembrolizumab. Ninety-four patients treated between May 2017 and July 2024 were analyzed for immune-related adverse events, laboratory-derived neutrophil-to-lymphocyte ratio cut-offs, mismatch repair status, and response patterns. Associations with progression-free and overall survival were assessed using Kaplan-Meier curves and Cox regression, with the optimal cut-off identified by ROC analysis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/immune-related-adverse-events-and-neutrophil-to-lymphocyte-ratio-as-prognostic-indicators-in-gynecologic-cancer-patients-receiving-pembrolizumab-a-real-world-analysis/352320/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/immune-related-adverse-events-and-neutrophil-to-lymphocyte-ratio-as-prognostic-indicators-in-gynecologic-cancer-patients-receiving-pembrolizumab-a-real-world-analysis/352320.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary objective of this study?","Question",{"text":112,"@type":113},"To determine whether immune-related adverse events and pretreatment neutrophil-to-lymphocyte ratio can serve as predictive biomarkers for treatment response and survival in gynecologic cancer patients treated with pembrolizumab.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were progression-free survival and overall survival evaluated?",{"text":117,"@type":113},"Progression-free survival and overall survival were analyzed using Kaplan-Meier curves and Cox regression models, while the optimal neutrophil-to-lymphocyte ratio cut-off was derived from ROC curve analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the study find regarding immune-related adverse events?",{"text":121,"@type":113},"Immune-related adverse events occurred in 55.3% of patients and were linked to higher objective response rate, longer progression-free survival, and improved overall survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352320,1790313744,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","TYPE Original Research PUBLISHED 21 January 2026  \nDOI 10.3389/fimmu.2025.1739447  \nOPEN ACCESS  \nEDITED BY  \nBastian Czogalla,  \nLMU Munich University Hospital, Germany  \nREVIEWED BY  \nGhanshyam H. Ghelani,  \nUpstate Medical University, United States Mustafa Murat Midik,  \nEge University Medical School, Türkiye  \n*CORRESPONDENCE  \nChen-Hsuan Wu  \n [chenhsuan5@gmail.com](chenhsuan5@gmail.com)  \nRECEIVED 04 November 2025  \nREVISED 27 December 2025  \nACCEPTED 30 December 2025  \nPUBLISHED 21 January 2026  \nCITATION  \nKao C-H, Lin H, Ou Y-C, Fu H-C, Tsai C-Cand Wu C-H (2026) Immune-related adverse events and neutrophil-to-lymphocyte ratio as prognostic indicators in gynecologic cancer patients receiving pembrolizumab: a realworld analysis.  \nFront. Immunol. 16:1739447 .  \ndoi: 10.3389/fimmu.2025.1739447  \nCOPYRIGHT  \n© 2026 Kao, Lin, Ou, Fu, Tsai and Wu. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nImmune-related adverse events and neutrophil-to-lymphocyte ratio as prognostic indicatorsin gynecologic cancer patients receiving pembrolizumab:  \na real-world analysis  \nChien-Hsiang Kao 1, Hao Lin 1, Yu-Che Ou1, Hung-Chun Fu 1, Ching-Chou Tsai 1 and Chen-Hsuan Wu 1,2*  \n1 Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan, 2Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan  \nObjective: To investigate whether immune-related adverse events and pretreatment neutrophil-to-lymphocyte ratio can serve as predictive biomarkers of treatment response and survival in patients with gynecologic cancer receiving pembrolizumab immunotherapy.  \nMethods: This retrospective study included 94 patients with gynecologic malignancies treated with pembrolizumab at Kaohsiung Chang Gung Memorial Hospital between May 2017 and July 2024 . Detailed clinical and laboratory data including the occurrence of immune-related adverse events, pretreatment neutrophil-to-lymphocyte ratio, mismatch repair (MMR) status, treatment response patterns, and patient demographics were collected. Progression-free survival and overall survival were analyzed using Kaplan-Meier curves and Cox regression models. The optimal neutrophil-to-lymphocyte ratio cut-off value for predicting the prognosis was determined using receiver operating characteristic curve analysis.  \nResults: Overall, immune-related adverse events occurred in 55 .3% of the patients and were associated with a signiﬁcantly higher objective response rate (ORR; 84 . 6% vs. 15.4%, p \u003C 0 . 001), longer progression-free survival (p \u003C 0 . 001), and improved overall survival (p \u003C 0 . 001) . Similarly, low neutrophil-tolymphocyte ratio (\u003C4.07) also predicted longer progression-free survival (HR: 0. 537, p = 0 . 043) and improved overall survival (HR: 0 . 328, p = 0 . 001) . Multivariate analysis conﬁrmed that both immune-related adverse events and low neutrophil-to-lymphocyte ratio were robust independent predictors of progression-free survival and overall survival. MMR-deﬁcient tumors were associated with a signiﬁcantly higher ORR (60 . 9% vs . 28. 9%, p = 0 . 011), although MMR status was not independently associated with survival in the ﬁnal multivariate models.  \nConclusion: The development of immune-related adverse events and low pretreatment neutrophil-to-lymphocyte ratio independently predicted improved therapeutic response and prolonged survival in gynecologic cancer patients treated with pembrolizumab. Their integration with tumor molecular  \nFrontiers in Immunology 01 [","cbCaicWKWz83NzXJ","https://ap.wps.com/l/cbCaicWKWz83NzXJ","pdf",1100264,11,"English","# Objective\n# Methods\n## Study design and data collection\n## Survival analysis\n# Results\n# Conclusion\n# Keywords","[{\"question\":\"What was the primary objective of this study?\",\"answer\":\"To determine whether immune-related adverse events and pretreatment neutrophil-to-lymphocyte ratio can serve as predictive biomarkers for treatment response and survival in gynecologic cancer patients treated with pembrolizumab.\"},{\"question\":\"How were progression-free survival and overall survival evaluated?\",\"answer\":\"Progression-free survival and overall survival were analyzed using Kaplan-Meier curves and Cox regression models, while the optimal neutrophil-to-lymphocyte ratio cut-off was derived from ROC curve analysis.\"},{\"question\":\"What did the study find regarding immune-related adverse events?\",\"answer\":\"Immune-related adverse events occurred in 55.3% of patients and were linked to higher objective response rate, longer progression-free survival, and improved overall survival.\"}]","Immune-related adverse events and neutrophil-to-lymphocyte ratio as prognostic indicators in gynecologic cancer patients receiving pembrolizumab - a real-world analysis | PDF",1790098943,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5fd7196537f006329c232f7ca38c1591.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/53a82049cbe097a3941650a676ae1b23.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0dd7c3ad72995464baf85dc155ec729.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b8286d61d0c0a8cab63f64860b035cd.webp",980,1385]